Published in Bioorg Med Chem Lett on March 28, 2009
A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med (2003) 29.55
Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med (2003) 27.97
Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science (2003) 18.34
Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol (2003) 9.09
Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science (2003) 3.92
Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol (2005) 1.73
Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease. Chem Biol (2006) 1.63
Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A (2004) 1.25
Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry (2004) 1.20
Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate. Biochem Biophys Res Commun (2004) 1.16
Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. J Med Chem (2005) 1.13
Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors. Bioorg Med Chem Lett (2007) 1.02
Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro. J Med Chem (2004) 1.01
Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters. Bioorg Med Chem (2005) 1.00
Biosynthesis of 4-methylproline in cyanobacteria: cloning of nosE and nosF genes and biochemical characterization of the encoded dehydrogenase and reductase activities. J Org Chem (2003) 0.95
Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors. Bioorg Med Chem Lett (2005) 0.93
Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CL(pro). Chem Biol Drug Des (2008) 0.88
Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors. J Med Chem (2006) 0.87
Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease. J Med Chem (2005) 0.87
Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease. Bioorg Med Chem (2008) 0.81
Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors. Chembiochem (2007) 0.80
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure (2008) 2.74
The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity (2008) 2.57
Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A (2004) 2.44
Identification of the functional core of the influenza A virus A/M2 proton-selective ion channel. Proc Natl Acad Sci U S A (2009) 2.32
CCR7-dependent cortex-to-medulla migration of positively selected thymocytes is essential for establishing central tolerance. Immunity (2006) 2.12
Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry (2006) 1.99
The linkage between protein folding and functional cooperativity: two sides of the same coin? Annu Rev Biophys Biomol Struct (2001) 1.90
Development of autoimmunity against transcriptionally unrepressed target antigen in the thymus of Aire-deficient mice. J Immunol (2005) 1.88
Aire-dependent production of XCL1 mediates medullary accumulation of thymic dendritic cells and contributes to regulatory T cell development. J Exp Med (2011) 1.87
Adding calorimetric data to decision making in lead discovery: a hot tip. Nat Rev Drug Discov (2009) 1.74
A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry (2003) 1.74
Real-time in vivo imaging of p16Ink4a reveals cross talk with p53. J Cell Biol (2009) 1.66
Effective treatment with oral administration of rebamipide in a mouse model of Sjögren's syndrome. Arthritis Rheum (2008) 1.51
Epsin N-terminal homology domains perform an essential function regulating Cdc42 through binding Cdc42 GTPase-activating proteins. Proc Natl Acad Sci U S A (2006) 1.50
ITC in the post-genomic era...? Priceless. Biophys Chem (2004) 1.50
Regulation of naive T cell function by the NF-kappaB2 pathway. Nat Immunol (2006) 1.49
Adaptive inhibitors of the HIV-1 protease. Prog Biophys Mol Biol (2005) 1.47
PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model. Neurobiol Dis (2006) 1.47
Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. Biochemistry (2003) 1.44
Mutations in the gene encoding fibroblast growth factor 10 are associated with aplasia of lacrimal and salivary glands. Nat Genet (2005) 1.43
Characterization of protein-protein interactions by isothermal titration calorimetry. Methods Mol Biol (2004) 1.43
Isothermal titration calorimetry to determine association constants for high-affinity ligands. Nat Protoc (2006) 1.43
Revised Japanese criteria for Sjögren's syndrome (1999): availability and validity. Mod Rheumatol (2004) 1.40
Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des (2008) 1.38
Compensating enthalpic and entropic changes hinder binding affinity optimization. Chem Biol Drug Des (2007) 1.38
Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography. Proc Natl Acad Sci U S A (2009) 1.34
Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci (2002) 1.33
Overcoming roadblocks in lead optimization: a thermodynamic perspective. Chem Biol Drug Des (2006) 1.31
Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors. J Med Chem (2012) 1.29
Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Biochemistry (2002) 1.27
Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain. J Virol (2009) 1.23
Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry (2004) 1.20
Binding thermodynamics of statins to HMG-CoA reductase. Biochemistry (2005) 1.20
Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biochemistry (2004) 1.16
Visualizing the dynamics of p21(Waf1/Cip1) cyclin-dependent kinase inhibitor expression in living animals. Proc Natl Acad Sci U S A (2007) 1.14
Interactions of HIV-1 proteins gp120 and Nef with cellular partners define a novel allosteric paradigm. Curr Protein Pept Sci (2004) 1.12
Structural parameterization of the binding enthalpy of small ligands. Proteins (2002) 1.10
Isothermal titration calorimetry. Curr Protoc Cell Biol (2004) 1.10
Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest (2002) 1.09
Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. J Med Chem (2008) 1.07
Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening. Bioorg Med Chem (2010) 1.06
Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-Ray and Thermodynamic Characterization. ACS Med Chem Lett (2013) 1.05
NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs (2006) 1.05
The active core in a triazole peptide dual-site antagonist of HIV-1 gp120. ChemMedChem (2010) 1.05
Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist. Acc Chem Res (2014) 1.04
Paclitaxel prodrugs: toward smarter delivery of anticancer agents. J Med Chem (2006) 1.03
A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease. Proteins (2004) 1.02
Possible involvement of stem cell factor and endothelin-1 in the emergence of pigmented squamous cell carcinoma in oral mucosa. J Oral Pathol Med (2007) 1.01
Finding a better path to drug selectivity. Drug Discov Today (2011) 0.99
The binding of HIV-1 protease inhibitors to human serum proteins. Biophys Chem (2003) 0.99
Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid. J Virol (2012) 0.98
Expression of the retinoblastoma protein RbAp48 in exocrine glands leads to Sjögren's syndrome-like autoimmune exocrinopathy. J Exp Med (2008) 0.98
Long-range cooperative interactions modulate dimerization in SARS 3CLpro. Biochemistry (2006) 0.98
Beta-turn Phe in HIV-1 Env binding site of CD4 and CD4 mimetic miniprotein enhances Env binding affinity but is not required for activation of co-receptor/17b site. Biochemistry (2002) 0.98
Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors. Biol Chem (2003) 0.97
Protease inhibition in African subtypes of HIV-1. AIDS Rev (2003) 0.97
High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry (2003) 0.97
Prevention and induction of autoimmune exocrinopathy is dependent on pathogenic autoantigen cleavage in murine Sjögren's syndrome. J Immunol (2002) 0.97
How much binding affinity can be gained by filling a cavity? Chem Biol Drug Des (2009) 0.97
Novel and efficient synthesis of difficult sequence-containing peptides through O-N intramolecular acyl migration reaction of O-acyl isopeptides. Chem Commun (Camb) (2003) 0.96
Thermodynamics-based drug design: strategies for inhibiting protein-protein interactions. Future Med Chem (2011) 0.96
Some binding-related drug properties are dependent on thermodynamic signature. Chem Biol Drug Des (2011) 0.96
Thermodynamic rules for the design of high affinity HIV-1 protease inhibitors with adaptability to mutations and high selectivity towards unwanted targets. Int J Biochem Cell Biol (2004) 0.95
Binding thermodynamics of the N-terminal peptide of the CCR5 coreceptor to HIV-1 envelope glycoprotein gp120. Biochemistry (2009) 0.95
Design of potent aspartic protease inhibitors to treat various diseases. Arch Pharm (Weinheim) (2008) 0.95
Development of autoimmune exocrinopathy resembling Sjögren's syndrome in estrogen-deficient mice of healthy background. Am J Pathol (2003) 0.94
The 'O-acyl isopeptide method' for the synthesis of difficult sequence-containing peptides: application to the synthesis of Alzheimer's disease-related amyloid beta peptide (Abeta) 1-42. J Pept Sci (2005) 0.94
Slower immune system aging in women versus men in the Japanese population. Immun Ageing (2013) 0.94
Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors. Biochemistry (2010) 0.94
Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases. Biol Chem (2004) 0.93
Optimization of CD4/gp120 inhibitors by thermodynamic-guided alanine-scanning mutagenesis. Chem Biol Drug Des (2013) 0.92
Design and synthesis of potent beta-secretase (BACE1) inhibitors with P1' carboxylic acid bioisosteres. Bioorg Med Chem Lett (2006) 0.92
Neonatal exposure to low-dose 2,3,7,8-tetrachlorodibenzo-p-dioxin causes autoimmunity due to the disruption of T cell tolerance. J Immunol (2009) 0.91
The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem (2005) 0.91
Crystal structures of the histo-aspartic protease (HAP) from Plasmodium falciparum. J Mol Biol (2009) 0.90
HIV protease inhibitors: peptidomimetic drugs and future perspectives. Curr Med Chem (2002) 0.90
"Click peptide" based on the "o-acyl isopeptide method": control of A beta1-42 production from a photo-triggered A beta1-42 analogue. J Am Chem Soc (2006) 0.90
YKL-40 secreted from adipose tissue inhibits degradation of type I collagen. Biochem Biophys Res Commun (2009) 0.90